Supplementary_table_2 – Supplemental material for KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
Marika Cinausero
Noemi Laprovitera
Giovanna De Maglio
Lorenzo Gerratana
Mattia Riefolo
Marianna Macerelli
Michelangelo Fiorentino
Elisa Porcellini
Vanessa Buoro
Francesco Gelsomino
Anna Squadrilli
Gianpiero Fasola
Massimo Negrini
Marcello Tiseo
Manuela Ferracin
Andrea Ardizzoni
10.25384/SAGE.10315562.v1
https://sage.figshare.com/articles/journal_contribution/Supplementary_table_2_Supplemental_material_for_KRAS_and_ERBB-family_genetic_alterations_affect_response_to_PD-1_inhibitors_in_metastatic_nonsquamous_NSCLC/10315562
<p>Supplemental material, Supplementary_table_2 for KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC by Marika Cinausero, Noemi Laprovitera, Giovanna De Maglio, Lorenzo Gerratana, Mattia Riefolo, Marianna Macerelli, Michelangelo Fiorentino, Elisa Porcellini, Vanessa Buoro, Francesco Gelsomino, Anna Squadrilli, Gianpiero Fasola, Massimo Negrini, Marcello Tiseo, Manuela Ferracin and Andrea Ardizzoni in Therapeutic Advances in Medical Oncology</p>
2019-11-16 13:06:44
anti-PD-1
immunotherapy
nivolumab
non-small cell lung cancer
pembrolizumab